A 58-year-old man is seen in the clinic six months after receiving a right coronary artery stent for unstable angina. His father died of coronary artery disease at the age of 50. The patient maintains a healthy diet and exercise regimen while adhering to his current medication regimen. 29 kg/m² is the BMI. The physical exam is unremarkable. After extensive discussion with the patient, evolocumab is added to his treatment plan. Which of the following is expected as an immediate result of this treatment?

Question

Quizplus · Accepted Answer

Eductional Objective: Binding of proprotein convertase subtilisin kexin 9 (PCSK9) to the hepatocyte cell surface LDL-R increases LDL-R degradation, resulting in decreased circulating LDL uptake. PCSK9 inhibitors (evolocumab, alirocumab, for example) reduce LDL-R degradation, resulting in increased LDL uptake in the liver and lower circulating LDL levels.

A 58-Year-Old Man Is Seen in the Clinic Six Months